Assembly Biosciences Inc. (ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, having delivered positive results from three of its clinical trials within the projected timeline, now looks ahead to its final data readouts of the year.
On June 25, 2025, the company announced positive topline efficacy, safety and pharmacokinetic (PK) results from the second cohort (400 mg) of its phase 1b study evaluating ABI-4334, an investigational next-generation capsid assembly modulator (CAM), in participants with chronic hepatitis B virus (HBV) infection.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.